Eutrig 10000

Product Overview

n

Eutrig 10000 is a sterile, lyophilized injectable preparation that delivers 10,000 International Units (IU) of human chorionic gonadotropin (HCG) per vial. Produced by Samarth Life Sciences Pvt Ltd, the product is supplied as a powder that must be reconstituted before use. Each box contains a single vial, with pack options of 3, 6, or 9 vials to accommodate different treatment lengths. The medication is classified under female infertility, reflecting its primary role in assisted reproductive techniques such as controlled ovarian stimulation and final oocyte maturation. Although the label lists “Indication: Erectile Dysfunction,” this use is not an approved indication in most regulatory jurisdictions and should be approached with caution.

nn

What is Eutrig 10000

n

Eutrig 10000 contains purified human chorionic gonadotropin, a glycoprotein hormone that mimics luteinizing hormone (LH) in the body. Naturally secreted by the placenta after implantation, HCG sustains the corpus luteum and supports early pregnancy. Clinically, the hormone is employed to trigger the final maturation of ovarian follicles, induce ovulation, and support the luteal phase in fertility protocols. The 10,000 IU dose provides a standardized potency that yields predictable ovulatory responses when administered at the appropriate follicular size. While the product’s labeling mentions erectile dysfunction, the scientific evidence for this indication is limited, and off‑label prescribing should only occur under medical supervision.

nn

Uses and Benefits

n

The most frequent application of Eutrig 10000 is in in‑vitro fertilization (IVF) cycles, where a single dose is given when the leading follicle reaches 18–20 mm to trigger ovulation. This timing increases the number of mature oocytes retrieved, improves fertilization rates, and can enhance overall pregnancy outcomes. In male patients, HCG is sometimes used off‑label to stimulate testosterone production in cases of hypogonadism, offering a potential therapeutic option. Additionally, HCG’s immunomodulatory effects have been explored in research settings, though these applications remain investigational. Patients may experience a subjective boost in energy or mood following treatment, likely related to hormonal fluctuations.

nn

How It Works

n

After injection, Eutrig 10000 binds to the LH/hCG receptor on ovarian theca cells, prompting androgen synthesis that is converted to estrogen by granulosa cells. This hormonal cascade replicates the natural pre‑ovulatory LH surge, leading to final oocyte maturation and ovulation. In men, the same receptor activation stimulates Leydig cells to produce testosterone, which can be beneficial for certain endocrine conditions. The injectable formulation ensures rapid absorption, delivering consistent serum concentrations that allow clinicians to coordinate treatment with ultrasound monitoring. The hormone’s half‑life ranges from 24 to 36 hours, providing a predictable window for ovulation without the need for continuous infusion.

nn

Dosage Guidelines

n

Dosage is individualized based on patient factors such as age, ovarian reserve, and prior response to stimulation. A typical protocol administers a single 10,000 IU intramuscular injection when the dominant follicle measures 18–20 mm in diameter, as confirmed by ultrasound. Some protocols employ a split dose of 5,000 IU followed by a second 5,000 IU injection 24 hours later to achieve a more gradual luteinization effect and reduce the risk of ovarian hyperstimulation syndrome (OHSS). In research exploring testosterone augmentation in men, weekly doses of 1,500–5,000 IU are commonly used under specialist supervision. All dosing should be prescribed by a qualified healthcare professional, with detailed documentation of administration dates and patient response.

nn

Side Effects

n

Most adverse events associated with Eutrig 10000 are mild and self‑limiting, including redness or pain at the injection site, headache, nausea, and temporary abdominal discomfort. Less common but more serious complications can include ovarian hyperstimulation syndrome (OHSS), characterized by rapid weight gain, abdominal distension, shortness of breath, and reduced urine output, as well as rare thromboembolic events in patients with pre‑existing risk factors. Patients should seek immediate medical attention if they experience severe pelvic pain, visual disturbances, or signs of a blood clot. For comprehensive safety data, refer to the FDA prescribing information FDA or reputable medical resources such as MedlinePlus MedlinePlus.

nn

Warnings and Precautions

n

Eutrig 10000 is contraindicated in individuals with known hypersensitivity to HCG or any excipients in the formulation. The drug should not be used in patients with active or suspected reproductive cancers, uncontrolled thyroid disease, or severe renal or hepatic impairment, as these conditions may worsen hormonal imbalances. Pregnant or breastfeeding women should avoid use unless a physician determines that the benefits outweigh potential risks. Individuals with a history of thromboembolic disorders require careful evaluation before therapy. Concomitant use of other hormonal medications may necessitate dose adjustments and close monitoring. Store the lyophilized powder refrigerated at 2‑8 °C and protect it from light until reconstitution; once mixed, the solution should be used promptly and discarded if left at room temperature for extended periods.

nn

Frequently Asked Questions

n

What is the recommended storage condition for Eutrig 10000?

n

Eutrig 10000 should be stored in a refrigerator maintained at a temperature between 2 °C and 8 °C, protected from light and moisture. The vial must remain sealed until the moment of use, and it should never be frozen, as freezing can degrade the hormone’s potency. Once the powder has been reconstituted with the appropriate diluent, the solution can be kept at room temperature for no longer than six hours before administration, after which it must be discarded to avoid loss of efficacy.

nn

Can Eutrig 10000 be used for male fertility issues?

n

Yes, human chorionic gonadotropin (HCG) is sometimes prescribed off‑label to stimulate testosterone production in men who have been diagnosed with primary or secondary hypogonadism. In clinical practice, weekly intramuscular doses ranging from 1,500 IU to 5,000 IU are used under the supervision of an endocrinologist to raise serum testosterone levels and improve symptoms such as low libido, fatigue, and reduced muscle mass. However, this use is not an officially approved indication for Eutrig 10000 in most regulatory jurisdictions, and patients should discuss potential benefits and risks with their specialist before initiating therapy.

nn

How does Eutrig 10000 differ from other HCG products?

n

Eutrig 10000 is manufactured by Samarth Life Sciences Pvt Ltd under strict Good Manufacturing Practice (GMP) conditions, ensuring a consistent potency of 10,000 IU per vial and a well‑characterized excipient profile. The product is supplied in a single‑vial format within a sealed box, offering clinicians flexibility in choosing pack sizes of 3, 6, or 9 vials. Compared with some multi‑dose vials from other manufacturers, Eutrig 10000 provides a lower risk of contamination after repeated punctures and may be preferred in protocols that require precise dosing and limited waste.

nn

Is a prescription required to purchase Eutrig 10000?

n

In the majority of countries, Eutrig 10000 is classified as a prescription‑only medication. A licensed physician must evaluate the patient’s medical history, perform any necessary laboratory assessments, and provide a written prescription before the product can be dispensed from a pharmacy or online retailer. This regulatory requirement ensures that the hormone is used only under professional supervision, minimizing the potential for misuse or inappropriate self‑administration.

nn

Where can I find scientific literature on HCG therapy?

n

Peer‑reviewed research on the use of human chorionic gonadotropin in reproductive medicine, endocrinology, and related fields can be accessed through PubMed, which indexes articles from reputable scientific journals. Additionally, the National Institutes of Health (NIH) offers evidence‑based resources and clinical trial databases that summarize current findings on HCG efficacy, dosing regimens, and safety profiles. These sources provide a solid foundation for understanding the therapeutic context of Eutrig 10000.

n